These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 4514339

  • 1. Plasma testosterone content of male patients with Parkinson's disease during L-dopa treatment with or without dopadecarboxylase inhibitor.
    Pekkarinen A, Rinne UK, Salokangas R, Siirtola T, Sonninen V.
    Acta Neurol Scand Suppl; 1972; 51():129-30. PubMed ID: 4514339
    [No Abstract] [Full Text] [Related]

  • 2. Treatment of Parkinsonism with a compound of L-dopa (Larodopa R) and a decarboxylase inhibitor (RO-46-4602).
    Holmsen R, Kvan L, Presthus J, Thoresen GB.
    Acta Neurol Scand Suppl; 1972; 51():121-2. PubMed ID: 4514336
    [No Abstract] [Full Text] [Related]

  • 3. Treatment of Parkinsonism with L-dopa and decarboxylase inhibitors. An electrophysiological study.
    Dietrichson P.
    Acta Neurol Scand Suppl; 1972; 51():111-3. PubMed ID: 4514333
    [No Abstract] [Full Text] [Related]

  • 4. [Treatment of Parkinson's disease with L-dopa alone or combined with Ro 4-4602].
    Barbeau A, Gillo-Joffroy L, Mars H, Arsenault A.
    Rev Can Biol; 1972; 31():Suppl:169-74. PubMed ID: 5052323
    [No Abstract] [Full Text] [Related]

  • 5. [Drug therapy of Parkinson's syndrome. Clinical long-term study using L-dopa and the drug conbination L-dopa-decarboxylase inhibitor].
    Christiani K, Möller WD.
    Munch Med Wochenschr; 1973 Apr 20; 115(16):711-3. PubMed ID: 4197759
    [No Abstract] [Full Text] [Related]

  • 6. Treatment of Parkinsonism with a combination of levodopa and the decarboxylase inhibitor and RO 46-4602 (a comparison with levodopa treatment alone).
    Dupont E, Hansen E, Melsens S, Parkenberg H, Holm P.
    Acta Neurol Scand Suppl; 1972 Apr 20; 51():115-7. PubMed ID: 4514334
    [No Abstract] [Full Text] [Related]

  • 7. Dopa-decarboxylase inhibitors.
    Lancet; 1973 May 05; 1(7810):979-80. PubMed ID: 4121597
    [No Abstract] [Full Text] [Related]

  • 8. Treatment of Parkinson's disease with levodopa combined with L-alpha-methyldopahydrazine, an inhibitor of extracerebral DOPA decarboxylase.
    Marsden CD, Barry PE, Parkes JD, Zilkha KJ.
    J Neurol Neurosurg Psychiatry; 1973 Feb 05; 36(1):10-4. PubMed ID: 4691682
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Treatment of parkinsonism with L-dopa and an L-aromatic amino acid inhibitor].
    Streifler M, Vardi J, Kesten M.
    Harefuah; 1972 Nov 01; 83(9):362-4. PubMed ID: 4669737
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Parkinson's syndrome. 4 years of experience in treatment with L Dopa associated with a decarboxylase inhibitor. Clinical and biochemical study].
    Tissot R, de Ajuriaguerra J.
    Nouv Presse Med; 1973 Feb 03; 2(5):315-6. PubMed ID: 4686226
    [No Abstract] [Full Text] [Related]

  • 13. [Advances in L-DOPA therapy for parkinsonism through combination with a decarboxylase inhibitor. Results of a long-term study].
    Wälzholz U, Schönfelder H.
    Nervenarzt; 1972 Oct 03; 43(10):531-2. PubMed ID: 4628192
    [No Abstract] [Full Text] [Related]

  • 14. [Therapy of Parkinsonism using L-dopa in combination with a decarboxylase inhibitor].
    Stammler A, Vielhaber K.
    Fortschr Neurol Psychiatr Grenzgeb; 1972 Oct 03; 40(10):564-8. PubMed ID: 4565521
    [No Abstract] [Full Text] [Related]

  • 15. L-dopa level in plasma, primary condition for the kinetic effect.
    Birkmayer W, Danielcyk W, Neumayer E, Riederer P.
    J Neural Transm; 1973 Oct 03; 34(2):133-43. PubMed ID: 4722571
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Dopa and decarboxylase inhibitors in Parkinson's disease].
    Pakkenberg H.
    Ugeskr Laeger; 1974 Feb 11; 136(7):377. PubMed ID: 4821980
    [No Abstract] [Full Text] [Related]

  • 19. Bensarazid with L-dopa in the treatment of parkinson's disease.
    Van Wieringen A.
    S Afr Med J; 1974 Feb 09; 48(6):206-9. PubMed ID: 4814495
    [No Abstract] [Full Text] [Related]

  • 20. [Treatment of Parkinson's syndrome with L-dopa and its methylated derivatives: 3-OMD and 4-OMD associated with a decarboxylase inhibitor. Clinical and biochemical study].
    Tissot R, Bartholini G, Constantinidis J, Eisenring JJ, Geissbühler F, Yanniotis G, de Ajuriaguerra J.
    Schweiz Med Wochenschr; 1973 Oct 20; 103(42):1466-74. PubMed ID: 4750149
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.